Acelity L.P. Inc. 10-K Annual Report March 2014

- Fourth quarter 2013 Centaur Guernsey L.P. Inc. (“Centaur” or the "Company") revenue of $469.8 million, up 6.8% from the prior-year period as reported and 7.3% from the prior-year period on a constant currency basis

- Fourth quarter 2013 loss from continuing operations of $51.7 million compared to $56.2 million for the prior-year period

- Fourth quarter 2013 total Adjusted EBITDA from continuing operations¹ of $191.9 million compared to $193.0 million for the prior-year period

- KCI closed on the previously-announced acquisition of Systagenix^TM

Highlights of the fourth quarter and year ended December 31, 2013

Centaur revenue for the fourth quarter of 2013 was $469.8 million, up from the prior-year comparable period by 7.3% on a constant currency basis. Our loss from continuing operations for the fourth quarter of 2013 was $51.7 million compared to $56.2 million in the prior-year period. Adjusted EBITDA from continuing operations were $191.9 million for the fourth quarter of 2013, compared to $193.0 million in the prior-year period.

Centaur revenue for the year ended December 31, 2013 was $1,758.9 million, up from the prior year by 1.2% on a constant currency basis. Our loss from continuing operations for the year ended December 31, 2013 was $555.4 million compared to $233.6 million in the prior-year period. Adjusted EBITDA from continuing operations were $717.1 million for the year ended December 31, 2013, compared to $735.8 million in the prior-year period.

On October 28, 2013, KCI closed on the previously-announced acquisition of Systagenix. Systagenix has a broad portfolio of innovative advanced wound care products with a focus on moist wound healing dressings - including PROMOGRAN PRISMA®, the collagen dressing market leader, TIELLE® (foam) and ADAPTIC® (non adherent contact layers). Systagenix distributes over 20 million advanced wound care dressings each month to more than 70 countries.

The successful completion of the Systagenix acquisition marks an important milestone in the advancement of our long-term strategy to be the global leader in transformational healing solutions. Over the coming quarters, we will continue integrating the Systagenix business into our broader wound care portfolio of products and therapies. As a result, we have renamed our business segments. Revenues related to KCI and Systagenix products are included within the Advanced Wound Therapeutics segment and revenue related to LifeCell is now reported under the Regenerative Medicine segment. We believe these segments reflect the nature of our businesses and are consistent with the manner in which we manage the Company.

“We are pleased with both the performance of our Regenerative Medicine business and the progress we continue to make in our Advanced Wound Therapeutics business,” said Joe Woody, President and Chief Executive Officer.

Our consolidated financial statements include Systagenix results for the period subsequent to the close date of the acquisition.

The following information was filed by Acelity L.P. Inc. on Thursday, March 6, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1557939/000155793914000013/a201310k.htm

View differences made from one year to another to evaluate Acelity L.P. Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Acelity L.P. Inc..

Continue

Assess how Acelity L.P. Inc.'s management team is paid from their Annual Proxy

Acelity L.P. Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Acelity L.P. Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.27: Amendment No. 4 To Senior Debt Facility

Exhibit 10.32: Offer Letter - Croxford

Exhibit 10.33: Promotion Letter - Croxford

Exhibit 10.34: Stay Bonus - Croxford

Exhibit 21.1: Listing Of Subsidiaries

Exhibit 31.1: Ceo Certification

Exhibit 32.1: Cfo Certification

Exhibit 32.1: Ceo Certification

Exhibit 32.2: Cfo Certification

CIK: 1557939
Form Type: 10-K Annual Report
Accession Number: 0001557939-14-000013
Submitted to the SEC: Mon Mar 10 2014 5:30:52 PM EST
Accepted by the SEC: Mon Mar 10 2014
Period: Tuesday, December 31, 2013
Industry: Surgical And Medical Instruments And Apparatus